Neuspera secured a Medicare payment win as CMS assigned its integrated sacral neuromodulation system to the same payment level as legacy implantable devices. Neuspera treats urinary urge incontinence with a miniaturized implant powered by an external device worn for about two hours daily. The approach avoids the implanted battery and replacement surgeries of conventional devices. The parity, which raises the payment rate by 11.8% to $22,150, gives Neuspera straightforward access to the roughly $1 billion legacy SNM market.